Clinical trials: Prostatic Disease
Urinary Incontinence
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease.
- Trial name
- NCT01215721
- Testing
- Vesicare
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Irvine
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen…
- Trial name
- VISION (NCT03511664)
- Testing
- 177Lu-PSMA-617, Best supportive/best standard of care
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 861 people
- Sponsor
- Endocyte
Prostate Cancer
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
- Trial name
- NCT00328614
- Testing
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Adenocarcinoma of the Prostate, Bone Metastases
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01807065
- Testing
- sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
A Safety and Feasibility Study of Mitotane in Prostate Cancer
1. The primary objective of this study is to assess the feasibility of treating patients with metastatic castration resistant prostate cancer with mitotane.
- Trial name
- NCT02057237
- Testing
- Mitotane
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: Docetaxel (a type of chemotherapy) Apalutamide (the study…
- Trial name
- NCT03093272
- Testing
- Leuprolide Acetate, Prednisone, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Specific Antigen Screening, Asymptomatic Bacteriuria
Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial
Investigators will evaluate clinical decision support nudges informed by behavioral science and directed at primary care clinicians.
- Conditions
- Prostate Specific Antigen Screening, Asymptomatic Bacteriuria, Type 2 Diabetes
- Trial name
- BEAGLE R33 (NCT04289753)
- Testing
- EHR clinical decision support nudges, Brief clinician education
- Where
- United States
- Volunteers
- 37,134 people
- Sponsor
- Northwestern University
Prostatic Neoplasms, Prostate Cancer
Fulvestrant in Hormone Refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have…
- Trial name
- NCT00476645
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Prostate Cancer, Bone Metastases
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
This study is intended to test an experimental new drug called, EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another…
- Trial name
- NCT00958477
- Testing
- EMD 525797
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Prostate Cancer
Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer
The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a…
- Trial name
- NCT00928174
- Testing
- IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Queen's Medical Center
Recurrent Prostate Cancer
Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.
- Trial name
- APP21 (NCT00583752)
- Testing
- Adenovirus/PSA Vaccine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- David M Lubaroff
Prostate Cancer
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer, and most recently trials have supported the use of transdermal estrogens (patch) in the patient population with a decreased risk of…
- Trial name
- NCT00176644
- Testing
- Transdermal Estradiol
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Ejaculatory Dysfunction, BPH
Outcomes and Efficacy of Ejaculatory Preserving Transurethral Resection of Prostate
The purpose of this study is to assess the outcomes and efficacy of ejaculatory preserving TURP in terms of voiding, erectile function, and ejaculation.
- Trial name
- NCT05914519
- Testing
- Ejaculatory Preserving Transurethral resection of prostate, Standard Transurethral Resection of prostate
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Prostate Cancer, Pneumoperitoneum
Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
- Trial name
- NCT02114164
- Testing
- AirSeal System, Standard Endopath
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- OhioHealth
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.